Related Experiment Video

Updated: Aug 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis

I G Naglie1, A S Detsky

  • 1Division of General Internal Medicine, Geriatric Medicine, and Clinical Epidemiology, Toronto Hospital, Ontario, Canada.

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|October 1, 1992
PubMed

Insights

The best treatment for elderly patients with chronic nonvalvular atrial fibrillation (CNVAF) depends on individual factors. Warfarin and aspirin offer similar benefits, but the optimal choice varies with medication effectiveness and side effects.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Health Economics

Background:

  • Chronic nonvalvular atrial fibrillation (CNVAF) poses significant health risks in elderly populations.
  • Treatment decisions for CNVAF in older adults require careful consideration of efficacy and patient outcomes.

Purpose of the Study:

  • To determine the preferred treatment strategy for elderly patients diagnosed with chronic nonvalvular atrial fibrillation (CNVAF).
  • To compare the long-term effectiveness of warfarin, aspirin, and no treatment for CNVAF in elderly cohorts.

Main Methods:

  • A Markov decision-analytic model was employed to simulate treatment outcomes over five years.
  • Quality-adjusted life years (QALYs) were calculated for male and female cohorts aged 70 and 75.
  • Sensitivity analyses were performed to assess the impact of varying effectiveness and utility parameters.

Main Results:

  • In baseline analyses, warfarin and aspirin yielded comparable 5-year QALYs for 70-year-old males (4.03 and 4.02, respectively), both superior to no treatment (3.95).
  • Similar results were observed across different age and sex cohorts.
  • Sensitivity analyses indicated that treatment outcomes were highly dependent on the effectiveness of aspirin and the disutility associated with warfarin.

Conclusions:

  • The optimal treatment strategy for CNVAF in elderly patients is not uniform.
  • Treatment choice should be individualized based on the specific disutility of warfarin therapy and the measured effectiveness of aspirin therapy.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...